Skip to main content
TipRanks
Go Ultimate75% OFF

Xenetic Biosciences (XBIO) AI Stock Analysis

347 Followers
XBIO

Xenetic Biosciences

(NASDAQ:XBIO)

Select Model
Rating:40Underperform
Price Target:$1.50â–²(7.14% Upside)
Action:downgraded
Date:11/13/26

The overall score is deeply pressured by the company's poor financial health, with significant cash burn and declining revenue, and a bearish technical outlook. The primary positive offset is the transformative Santersus AG merger, which introduces a new strategic direction and clinical catalysts, though its execution risk and dilutive all-stock structure temper its immediate benefit.

Positive Factors
Debt-Free Balance SheetEssentially no debt gives Xenetic a conservative capital structure and avoids a recurring interest burden. This preserves financial flexibility for research, operations, or strategic transactions, while reducing solvency pressure as the company works to improve its still-weak operating performance.
Negative Factors
Persistent UnprofitabilityXenetic combines a small and volatile revenue base with a deeply negative net margin, showing that the business is not yet self-sustaining. Continued operating losses limit internal investment capacity and make future progress dependent on improving revenue, costs, or external funding.

Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%XBIO-44.44%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.28M
Dividend Yield
―
Average Volume (3M)
73.39K
Price to Earnings (P/E)
-0.9
Beta (1Y)
0.82
Revenue Growth
3.50%
EPS Growth
22.76%
Country
US
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack di...

Xenetic Biosciences Financial Statement Overview

Summary

Financial performance is critically weak. The company suffers from persistent, significant net losses and a 9.3% TTM revenue decline, despite a 100% gross margin. The only mitigating factor is a debt-free balance sheet, but this is overshadowed by rapidly eroding equity and deep negative returns.

Income Statement

18Very Negative

Balance Sheet

65Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.96M2.98M2.50M2.54M1.71M1.16M
Gross Profit2.96M2.98M2.50M2.54M1.71M1.16M
EBITDA-3.66M-2.68M-3.81M-4.13M-6.53M-5.61M
Net Income-3.66M-2.68M-3.96M-4.13M-6.55M-5.65M
Balance Sheet
Total Assets6.32M8.36M6.90M10.61M14.72M19.82M
Cash, Cash Equivalents and Short-Term Investments5.81M7.88M6.17M8.98M13.10M18.24M
Total Debt0000027.04K
Total Liabilities1.90M968.02K894.26K809.59K1.07M1.42M
Stockholders Equity4.41M7.40M6.01M9.80M13.65M18.39M
Cash Flow
Free Cash Flow-2.32M-2.29M-2.82M-4.11M-5.15M-4.74M
Operating Cash Flow-2.32M-2.29M-2.82M-4.11M-4.65M-4.74M
Investing Cash Flow0000-500.00K0
Financing Cash Flow4.00M4.00M00011.45M

Xenetic Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price1.40

Price Trends

50DMA2.14Negative
100DMA2.70Negative
200DMA2.79Negative

Market Momentum

MACD-0.20Positive
RSI29.94Positive
STOCH20.96Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 1.40 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 2.14, and below the 200-day MA of 2.79, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 20.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.

Xenetic Biosciences Risk Analysis

Xenetic Biosciences disclosed 82 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The issuance of Company Common Stock in the Acquisition pursuant to the Exchange Agreement, the resulting change in control from the Acquisition, the amendment to the articles of incorporation of Xenetic increasing the authorized shares of Common Stock, and an amendment to the Xenetic equity plan must be approved by Xenetic stockholders. Failure to obtain these approvals and failure of any other closing conditions to the Exchange Agreement would prevent the Closing and Acquisition.Q3, 2026
2.The Exchange Ratio set forth in the Exchange Agreement is not adjustable based on the market price of our common stock, so the Acquisition consideration at the Closing may have a greater or lesser value than at the time the Exchange Agreement was signed.Q3, 2026
3.Some Xenetic officers and directors have interests in the Acquisition that are different from our stockholders and that may influence them to support or approve the Acquisition without regard to the interests of our stockholders.Q3, 2026

Xenetic Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

XBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
APREAPRE55Neutral$7.00M-0.33-44.26%―-99.32%67.31%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
XBIOXBIO40Underperform$3.61M-0.89-58.96%―3.50%22.76%
HCWBHCWB38Underperform$2.31M-0.03-63.04%―1502.05%77.12%

* Healthcare Sector Average

Performance Comparison

-50%0%50%XBIOERNAAPREHCWBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
XBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
XBIOXenetic Biosciences, Inc.1.40-1.06-43.09%
ERNAEterna Therapeutics Inc.1.36-30.89-95.78%
APREAprea Therapeutics, Inc.0.23-0.94-80.43%
HCWBHcw Biologics, Inc.0.75-12.27-94.25%

Xenetic Biosciences Corporate Events

Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance

Xenetic Updates Investors on Santersus Share Exchange Plans

Neutral
Sep 23, 2026

On September 23, 2026, Xenetic Biosciences released an updated investor presentation tied to its pending share exchange transaction with Swiss-based Santersus AG, a deal first announced on September 16, 2026. The company also confirmed it will file a...

Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance

Xenetic Biosciences to Acquire Santersus AG in Merger

Positive
Sep 16, 2026

On September 14, 2026, Xenetic Biosciences agreed to acquire all outstanding shares of Swiss medical device group Santersus AG via an all-stock share exchange that will make Santersus a wholly owned subsidiary, with its investors owning roughly 85 pe...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026